Tracking

Friday, 29 November 2019

CCC publication: Induction of serum CXCL10 by tebentafusp, a gp100-CD3 bispecific fusion protein, was associated with survival in uveal melanoma in a Phase I/II Study

Citation: Source Journal for ImmunoTherapy of Cancer. 2019, 7
Author: Butler M.; Higgs B. (brandon.higgs@immunocore.com); McAlpine C.; Sacco J.; Hassel J.; Abdullah S.; Ranade K.; Carvajal R.